Genmab Phase 3 LiGeR-HN1 Trial Shows Petosemtamab Combination Cuts Head-and-Neck Cancer Death Risk 50%

This is a valid new clinical-study development: Genmab reported first-interim Phase 3 results showing a statistically significant overall-survival benefit, a 50% reduction in the risk of death, and improved objective response rate for petosemtamab plus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head-and-neck squamous cell carcinoma. The result has substantial forward relevance because Genmab plans regulatory engagement and fuller data disclosure, although no regulatory approval has yet been reported. Importance is set below the maximum because the evidence is topline and interim rather than a final result or approval; surprise is material but market expectations are not provided. The exact trial-readout time is not stated, so the timestamp uses the earliest supplied report timestamp with moderate timing confidence. GMAB is directly affected, while MRK has a clear but conditional connection through pembrolizumab; indirect diagnostic, laboratory, CDMO, and competitor relationships were excluded because no program-specific commercial impact is established.